AGE-RELATE MACULAR DEGENERATION SUCCESSFULLY TREATED WITH QIAPI 1™. CASE REPORT

AGE-RELATE MACULAR DEGENERATION SUCCESSFULLY TREATED WITH QIAPI 1™. CASE REPORT

Arturo Solís Herrera, MD, PhD. María del Carmen Arias Esparza, MD, MsC. Paola Eugenia Solís Arias, MD, Ophthalmologist.

Human Photosynthesis™ Research Centre. Aguascalientes 20000, México

Age-related macular degeneration (AMD) is a disease leading to severe visual loss and legal blindness in the elderly population overall in cold countries. Its pathogenesis, likely multifactorial, involving a complex and dynamic interaction of metabolic, functional, genetic, and environmental factors, remains poorly understood. For these reasons currently used therapeutic approaches are way beyond to be effective.
Two types of AMD are distinguished: the dry and the wet form. Main risk factors include advanced age, genetic predispositions, environmental determinants, history of exposure to intensive light and smoking. Till now, there is no approved therapy for dry AMD, although several agents/treatments are currently in clinical trials.
Since upregulated vascular endothelial growth factor (VEGF) is a predominant proangiogenic factor in CNV. the wet AMD can be treated with intra-vitreous application of “anti-VEGF” agents; however, their clinical results are disappointing.
In this article, we report clinical results of a novel approach, based in our discovery of the unsuspected intrinsic capacity of human being to transform the power of the sunlight into chemical energy, throughout the dissociation of the water molecule, like plants do it.

Keywords: Macula, degeneration, water, neovascularization, edema, retina.

Free Full-text PDF

How to cite this article:
Arturo Solís Herrera, María del Carmen Arias Esparza, Paola Eugenia Solís Arias. Age-relate macular degeneration successfully treated with QIAPI 1™. Case Report. International Journal of Aging Research, 2022, 5:96. DOI: 10.28933/ijoar-2022-03-0605

References:

1. Tamaki Y. [Novel approach for management of age-related macular degeneration–antiangiogenic therapy and retinal regenerative therapy]. Nippon Ganka Gakkai Zasshi. 2007 Mar;111(3):232-68; discussion 269. Japanese. PMID: 17402564.
2. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 2006 May-Jun;58(3):353-63. PMID: 16845209.
3. Spraul CW, Lang GE, Grossniklaus HE, Lang GK. Histologic and morphometric analysis of the choroid, Bruch’s membrane, and retinal pigment epithelium in postmortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes. Surv Ophthalmol. 1999 Oct;44 Suppl 1:S10-32. doi: 10.1016/s0039-6257(99)00086-7. PMID: 10548114.
4. Ozkiris A. Anti-VEGF agents for age-related macular degeneration. Expert Opin Ther Pat. 2010 Jan;20(1):103-18. doi: 10.1517/13543770902762885. PMID: 20021287.
5. Rejdak R, Szkaradek M, Grieb P, Jünemann AG. Emerging therapies for the treatment of wet age-related macular degeneration–VEGF Trap-Eye. Klin Oczna. 2011;113(10-12):376-8. PMID: 22384659.
6. Akuffo K. O., Beatty S., Peto T., Stack J., Stringham J., Kelly D., et al. (2017). The Impact of Supplemental Antioxidants on Visual Function in Nonadvanced Age-Related Macular Degeneration: A Head-To-Head Randomized Clinical Trial. Invest. Ophthalmol. Vis. Sci. 58, 5347. 10.1167/iovs.16-21192 –
7. Nowak JZ, Bienias W. Zwyrodnienie plamki zwiazane z wiekiem (AMD): etiopatogeneza i strategie terapeutyczne [Age-related macular degeneration (AMD): etiopathogenesis and therapeutic strategies]. Postepy Hig Med Dosw (Online). 2007;61:83-94. Polish. PMID: 17369776.
8. Herrera AS. Towards a new ophthalmic biology and physiology: the unsuspected intrinsic property of melanin to dissociate the water molecule. MOJ Cell Sci Rep. 2017;4(2):49‒60. DOI: 10.15406/mojcsr.2017.04.00084
9. Hydrogen | H2 – PubChem (nih.gov)